Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

被引:0
|
作者
Geerts, Julie F. M. [1 ,2 ]
van der Zijden, Charlene J. [2 ]
van der Sluis, Pieter C. [2 ]
Spaander, Manon C. W. [3 ]
Nieuwenhuijzen, Grard A. P. [1 ]
Rosman, Camiel [4 ]
van Laarhoven, Hanneke W. M. [5 ,6 ]
Verhoeven, Rob H. A. [5 ,6 ,7 ]
Wijnhoven, Bas P. L. [2 ]
Lagarde, Sjoerd M. [2 ]
Mostert, Bianca [8 ]
机构
[1] Catharina Hosp, Dept Surg, NL-5623 EJ Eindhoven, Netherlands
[2] Erasmus MC, Dept Surg, Canc Inst, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[4] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 GA Nijmegen, Netherlands
[5] Univ Amsterdam, Dept Med Oncol, Amsterdam UMC Locat, NL-1081 HV Amsterdam, Netherlands
[6] Canc Ctr Amsterdam, Canc Treatment & Qual Life, NL-1105 AZ Amsterdam, Netherlands
[7] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, NL-3511 LC Utrecht, Netherlands
[8] Erasmus MC, Dept Med Oncol, Canc Inst, NL-3015 GD Rotterdam, Netherlands
关键词
esophageal cancer; gastro-esophageal cancer; gastric cancer; neoadjuvant chemotherapy; esophagectomy; STAGING LAPAROSCOPY; ADENOCARCINOMA; SURVIVAL; 5-FLUOROURACIL; CAPECITABINE; OXALIPLATIN;
D O I
10.3390/cancers16071291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods: Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015-2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77-1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09-1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08-1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05-2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Gastric histology in patients with carcinoma at the gastro-esophageal junction
    El-Zimaity, HMT
    Katsuyama, T
    Ota, H
    Watanabe, H
    Hattori, T
    Graham, DY
    GASTROENTEROLOGY, 2001, 120 (05) : A249 - A249
  • [22] VERTICAL GASTRIC PLICATION - AN OPERATION FOR GASTRO-ESOPHAGEAL REFLUX
    TAYLOR, TV
    KNOX, RA
    PULLAN, BR
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1989, 71 (01) : 31 - 36
  • [23] GASTRIC-EMPTYING IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX
    MCCALLUM, RW
    BERKOWITZ, DM
    LERNER, E
    GASTROENTEROLOGY, 1981, 80 (02) : 285 - 291
  • [24] DELAYED GASTRIC-EMPTYING AND GASTRO-ESOPHAGEAL REFLUX
    DIMLER, M
    JOURNAL OF PEDIATRICS, 1981, 99 (03): : 504 - 504
  • [25] Gastro-esophageal reflux through gastric antisecretory drugs
    Jian, R.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 (8-9): : 614 - 624
  • [26] GASTRIC-EMPTYING IN GASTRO-ESOPHAGEAL REFLUX OF INFANCY
    HILLEMEIER, AC
    GRYBOSKI, JD
    LANGE, R
    MCCALLUM, RW
    CLINICAL RESEARCH, 1980, 28 (03): : A630 - A630
  • [27] Gastric histology in patients with carcinoma at the gastro-esophageal junction
    El-Zimaity, HMT
    Katsuyama, T
    Ota, H
    Watanabe, H
    Hattori, T
    Graham, DY
    GUT, 2001, 49 : A65 - A65
  • [28] TRG as indicator of efficacy of FLOT versus FOLFOX in perioperative chemotherapy for resectable gastric cancer patients (single institution experience).
    Beliak, Natalia P.
    Orlova, Rashida
    Kutukova, Svetlana
    Zhukova, Natalia V.
    Balashov, Pavel
    Usmanov, Nazif
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Endoscopic or Surgical Resection for Gastro-Esophageal Cancer
    Gockel, Ines
    Hoffmeister, Albrecht
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (31-32): : 513 - +
  • [30] THE VALUE OF POSSUM IN SURGERY OF GASTRO-ESOPHAGEAL CANCER
    Yang, L. W.
    Wang, H. Y.
    Guo, C. W.
    Han, Q. S.
    Luan, Y. C.
    Li, Z. F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 118 : 23 - 23